ZEVRA THERAPEUTICS, INC. ZVRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-0.84
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $106.5M | $83.2M | — | -$2.4M | $154.7M |
| 2024 | $23.6M | -$105.5M | — | -$69.7M | $39.7M |
| 2023 | $27.5M | -$46.0M | — | -$33.8M | $61.9M |
| 2022 | $10.2M | -$26.8M | — | -$18.8M | $75.1M |
| 2021 | $28.6M | -$8.6M | — | $10.3M | $101.7M |
| 2020 | $13.3M | -$12.8M | — | -$2.0M | -$66.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance | 2026-06-22 | Sell | 34,557 | $12.68 |
| Thompson Rahsaan | Chief Legal & Compliance | 2026-06-21 | Option exercise | 66,667 | — |
| Thompson Rahsaan | Chief Legal & Compliance | 2026-05-11 | Sell | 1,794 | $11.30 |
| Bode John B | director | 2026-03-24 | Option exercise | 39,200 | $4.97 |
| Bode John B | director | 2026-03-24 | Option exercise | 39,200 | $4.89 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.84 (distress)
- Working capital / assets 0.645
- Retained earnings / assets -1.482
- EBIT / assets -0.221
- Equity / liabilities 1.189
Source: SEC EDGAR filings · CIK 0001434647 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.